| Cryopyrin activates the inflammasome in response to toxins and ATP S Mariathasan, DS Weiss, K Newton, J McBride, K O'Rourke, ... Nature 440 (7081), 228-232, 2006 | 3444 | 2006 |
| A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE) KC Kalunian, JT Merrill, R Maciuca, JM McBride, MJ Townsend, X Wei, ... Annals of the rheumatic diseases 75 (1), 196-202, 2016 | 368 | 2016 |
| Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice J Lau, J Cheung, A Navarro, S Lianoglou, B Haley, K Totpal, L Sanders, ... Nature communications 8 (1), 14572, 2017 | 349 | 2017 |
| Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma D Dornan, F Bennett, Y Chen, M Dennis, D Eaton, K Elkins, D French, ... Blood, The Journal of the American Society of Hematology 114 (13), 2721-2729, 2009 | 296 | 2009 |
| Leukocyte functional antigen 1 lowers T cell activation thresholds and signaling through cytohesin-1 and Jun-activating binding protein 1 OD Perez, D Mitchell, GC Jager, S South, C Murriel, J McBride, ... Nature immunology 4 (11), 1083-1092, 2003 | 294 | 2003 |
| Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo‐controlled, double‐blind, dose‐escalation study JM McBride, J Jiang, AR Abbas, A Morimoto, J Li, R Maciuca, ... Arthritis & Rheumatism 64 (11), 3666-3676, 2012 | 209 | 2012 |
| Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor R Deng, D Bumbaca, CV Pastuskovas, CA Boswell, D West, KJ Cowan, ... MAbs 8 (3), 593-603, 2016 | 184 | 2016 |
| IL-10 alters DC function via modulation of cell surface molecules resulting in impaired T-cell responses JM McBride, T Jung, JE de Vries, G Aversa Cellular immunology 215 (2), 162-172, 2002 | 169 | 2002 |
| Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE WP Kennedy, R Maciuca, K Wolslegel, W Tew, AR Abbas, C Chaivorapol, ... Lupus science & medicine 2 (1), e000080, 2015 | 128 | 2015 |
| DCDT2980S, an anti-CD22-monomethyl auristatin E antibody–drug conjugate, is a potential treatment for non-Hodgkin lymphoma D Li, KA Poon, SF Yu, R Dere, MA Go, J Lau, B Zheng, K Elkins, ... Molecular cancer therapeutics 12 (7), 1255-1265, 2013 | 107 | 2013 |
| Generation and protective ability of influenza virus–specific antibody-dependent cellular cytotoxicity in humans elicited by vaccination, natural infection, and experimental … S Jegaskanda, C Luke, HD Hickman, MY Sangster, WF Wieland-Alter, ... The Journal of infectious diseases 214 (6), 945-952, 2016 | 104 | 2016 |
| Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma AG Polson, M Williams, AM Gray, RN Fuji, KA Poon, J McBride, H Raab, ... Leukemia 24 (9), 1566-1573, 2010 | 98 | 2010 |
| Interleukin 10 regulates cell surface and soluble LIR‐2 (CD85d) expression on dendritic cells resulting in T cell hyporesponsiveness in vitro BG Beinhauer, JM McBride, P Graf, E Pursch, M Bongers, M Rogy, ... European journal of immunology 34 (1), 74-80, 2004 | 95 | 2004 |
| FcRL5 as a target of antibody–drug conjugates for the treatment of multiple myeloma K Elkins, B Zheng, MA Go, D Slaga, C Du, SJ Scales, SF Yu, J McBride, ... Molecular cancer therapeutics 11 (10), 2222-2232, 2012 | 93 | 2012 |
| Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney … JH Ishida, A Patel, AK Mehta, P Gatault, JM McBride, T Burgess, ... Antimicrobial agents and chemotherapy 61 (2), 10.1128/aac. 01794-16, 2017 | 92 | 2017 |
| Two escape mechanisms of influenza A virus to a broadly neutralizing stalk-binding antibody N Chai, LR Swem, M Reichelt, H Chen-Harris, E Luis, S Park, A Fouts, ... PLoS pathogens 12 (6), e1005702, 2016 | 91 | 2016 |
| Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade R Banchereau, AS Chitre, A Scherl, TD Wu, NS Patil, P de Almeida, ... Journal for ImmunoTherapy of Cancer 9 (4), 2021 | 84 | 2021 |
| Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials DT Rubin, I Dotan, A DuVall, Y Bouhnik, G Radford-Smith, PDR Higgins, ... The lancet Gastroenterology & hepatology 7 (1), 17-27, 2022 | 70 | 2022 |
| The role of integrins in the pathogenesis of inflammatory bowel disease: approved and investigational anti‐integrin therapies I Dotan, M Allez, S Danese, M Keir, S Tole, J McBride Medicinal research reviews 40 (1), 245-262, 2020 | 69 | 2020 |
| Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model JM McBride, JJ Lim, T Burgess, R Deng, MA Derby, M Maia, P Horn, ... Antimicrobial agents and chemotherapy 61 (11), 10.1128/aac. 01154-17, 2017 | 66 | 2017 |
